Title : Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.

Pub. Date : 2012 Nov

PMID : 23090888






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens